Haemonetics Corporation $HAE Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC cut its position in shares of Haemonetics Corporation (NYSE:HAE) by 68.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,540 shares of the medical instruments supplier’s stock after selling 9,679 shares during the period. SG Americas Securities LLC’s holdings in Haemonetics were worth $256,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the company. AQR Capital Management LLC increased its holdings in shares of Haemonetics by 372.8% during the 3rd quarter. AQR Capital Management LLC now owns 2,128,878 shares of the medical instruments supplier’s stock worth $102,814,000 after buying an additional 1,678,630 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in Haemonetics by 994.7% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,380,102 shares of the medical instruments supplier’s stock valued at $110,615,000 after acquiring an additional 1,254,035 shares during the last quarter. Millennium Management LLC lifted its holdings in Haemonetics by 4,296.3% in the third quarter. Millennium Management LLC now owns 773,179 shares of the medical instruments supplier’s stock valued at $37,685,000 after acquiring an additional 755,592 shares during the last quarter. North Peak Capital Management LLC grew its position in Haemonetics by 204.4% in the fourth quarter. North Peak Capital Management LLC now owns 1,102,992 shares of the medical instruments supplier’s stock worth $88,405,000 after acquiring an additional 740,626 shares during the period. Finally, Invenomic Capital Management LP increased its stake in Haemonetics by 1,691.5% during the third quarter. Invenomic Capital Management LP now owns 498,317 shares of the medical instruments supplier’s stock worth $24,288,000 after acquiring an additional 470,502 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Price Performance

HAE stock opened at $76.05 on Friday. The company has a current ratio of 2.95, a quick ratio of 1.87 and a debt-to-equity ratio of 1.53. The company has a market capitalization of $3.46 billion, a PE ratio of 37.65, a P/E/G ratio of 1.51 and a beta of 0.52. Haemonetics Corporation has a 12-month low of $47.31 and a 12-month high of $87.32. The business’s fifty day moving average price is $68.35 and its 200 day moving average price is $66.36.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.01. The company had revenue of $346.35 million during the quarter, compared to analysts’ expectations of $336.83 million. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.Haemonetics’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same period last year, the business posted $1.24 EPS. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. On average, sell-side analysts anticipate that Haemonetics Corporation will post 5.22 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on HAE shares. JPMorgan Chase & Co. reduced their target price on Haemonetics from $74.00 to $62.00 and set a “neutral” rating on the stock in a research report on Friday, May 8th. Citigroup reissued a “neutral” rating on shares of Haemonetics in a research report on Wednesday. Mizuho boosted their price objective on shares of Haemonetics from $70.00 to $85.00 and gave the company an “outperform” rating in a report on Monday, June 15th. Robert W. Baird set a $67.00 target price on shares of Haemonetics in a research report on Friday, May 8th. Finally, Barrington Research lowered their target price on shares of Haemonetics from $94.00 to $89.00 and set an “outperform” rating for the company in a research note on Tuesday, May 12th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $78.33.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.